디페리프론(Deferiprone) 시장 : 형태별, 용도별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Deferiprone Market By Form , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,152,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,304,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

디페리프론 시장

디페리프론 시장은 2023년 3,340만 달러로 평가되며 2024-2033년간 연평균 3.2% 성장하여 2033년에는 4,590만 달러에 달할 것으로 예측됩니다.

데페리프론은 수혈이나 주요 지중해 빈혈로 인한 철분 과다증을 치료하는 약물로 사용되는 화합물입니다. 디페리프론의 역할은 철분을 킬레이트화하여 소변을 통해 혈류에서 제거하는 것입니다. 디페리프론은 정제 또는 복용액으로 섭취되며 상부 소화관에서 쉽게 흡수됩니다.

데페리프론 시장의 성장은 지중해 빈혈, 겸상 적혈구 빈혈 등 정기적인 수혈이 필요한 질환의 유병률 증가가 큰 원동력이 되고 있습니다. 또한 철분 장애에 대한 인식이 높아지면서 철분 과다증에 대한 데페리프론의 채택이 증가하고 있습니다. 또한, 여러 국가의 정부가 만성 질환 및 철분 관련 질환의 치료 능력 향상에 주력하고 있으며, 이는 데페리프론에 대한 수요를 증가시키고 있습니다. 이는 시장 개척을 촉진하고 있습니다. 현재 시장에서는 데페리프론의 용도 확대에 대한 움직임이 나타나고 있으며, American Association for Cancer Research Journals에 게재된 논문에 따르면, 데페리프론은 전이성 난소암을 제어하는 대체 면역치료제로 작용할 것으로 예상되고 있습니다. 역할을 할 것으로 예상되고 있습니다.

그러나 데페리프론의 부적절한 투여 또는 과다 투여는 무과립구증 및 호중구감소증과 같은 심각한 부작용을 유발하여 그 유용성을 제한하고 시장 성장을 저해합니다. 또한, 이 의약품은 데스페리옥사민, 데페라시록스 등 동등하게 효율적인 대안과 치열한 경쟁에 직면해 있습니다. 이는 데페리프론 시장 개척을 상당히 억제하고 있습니다. 이와는 대조적으로, 개인 맞춤형 의료의 인기가 높아짐에 따라 시장에 새로운 길을 열어줄 것으로 예상됩니다. 개인 맞춤형 의료는 개인의 건강 상태와 신체 상태에 따라 약이나 치료를 제공하는 것을 말합니다. 맞춤형 투약은 인체에 부작용을 일으킬 가능성이 거의 없기 때문에 데페리프론의 보급을 촉진할 것으로 예상됩니다.

부문별 리뷰

데페리프론 시장은 형태, 용도, 유통 채널, 지역으로 구분됩니다. 형태에 따라 시장은 정제와 기타로 나뉩니다. 용도별로는 수혈성 철분 과다증과 NTDT에 의한 철분 과다증으로 나뉩니다. 유통 채널별로는 병원 약국, 드럭스토어 및 소매 약국, 온라인 공급업체로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

형태별로는 정제 부문이 2023년 시장을 장악했습니다.

용도별로는 수혈성 철분 과다증 부문이 2033년까지 높은 시장 점유율을 차지할 것으로 예상됩니다.

유통 채널별로는 예측 기간 동안 온라인 제공업체 부문이 최대 주주가 될 것으로 예상됩니다.

지역별로는 북미가 2023년 시장에서 가장 높은 수익을 올린 것으로 나타났습니다.

본 보고서에서 가능한 커스터마이징(추가 비용 및 일정이 있습니다.)

• 국가, 지역 및 세계 수준의 환자/역학 데이터
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 프로파일
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 데페리프론 시장 : 형태별

• 시장 개요
• 정제
• 기타

제5장 데페리프론 시장 : 용도별

• 시장 개요
• 수혈성 철 과잉증
• NTDT에 의한 철과잉증

제6장 데페리프론 시장 : 유통 채널별

• 시장 개요
• 병원 약국
• 드럭스토어
• 온라인 공급업체

제7장 데페리프론 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국 디페리프론 시장
  • 캐나다 디페리프론 시장
  • 멕시코 디페리프론 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스 디페리프론 시장
  • 독일 디페리프론 시장
  • 이탈리아 디페리프론 시장
  • 스페인 디페리프론 시장
  • 영국 디페리프론 시장
  • 기타 유럽 디페리프론 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국 디페리프론 시장
  • 일본 디페리프론 시장
  • 인도 디페리프론 시장
  • 한국 디페리프론 시장
  • 호주 디페리프론 시장
  • 기타 아시아태평양 디페리프론 시장
• 라틴아메리카/중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질 디페리프론 시장
  • 남아프리카공화국 디페리프론 시장
  • 사우디아라비아 디페리프론 시장
  • 기타 라틴아메리카/중동 및 아프리카 디페리프론 시장

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Apotex Inc
• Cipla Limited
• VHB Life Sciences Limited
• Taro Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Novartis International AG
• Chiesi Farmaceutici S.p.A
• Zydus Cadila
• Cipla Inc.
• Pfizer

LSH

영문 목차

영문목차

Deferiprone Market

The deferiprone market was valued at $33.4 million in 2023 and is projected to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.

Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.

The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of metastatic ovarian cancer.

However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual's health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum to no possibility of causing side effects to the human body.

Segment Review

The deferiprone market is segmented into form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023.

As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.

Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.

Region wise, North America was the highest revenue generator in the market in 2023.

Competition Analysis

The key players operating in the global deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Taro Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A, Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Form

• Tablets
• Others

By Application

• Transfusional Iron Overload
• NTDT Caused Overload.

By Distribution Channel

• Hospital Pharmacies
• Drug store retail pharmacies
• Online providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Apotex Inc
• Cipla Limited
• VHB Life Sciences Limited
• Taro Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Novartis International AG
• Chiesi Farmaceutici S.p.A
• Zydus Cadila
• Cipla Inc.
• Pfizer

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: DEFERIPRONE MARKET, BY FORM

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Form
• 4.2. Tablets
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Others
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: DEFERIPRONE MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Transfusional Iron Overload
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. NTDT Caused Overload.
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Distribution Channel
• 6.2. Hospital Pharmacies
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Drug Store Retail Pharmacies
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Online Providers
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: DEFERIPRONE MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Form
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By Distribution Channel
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Deferiprone Market
    • 7.2.6.1. Market Size and Forecast, By Form
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By Distribution Channel
  • 7.2.7. Canada Deferiprone Market
    • 7.2.7.1. Market Size and Forecast, By Form
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By Distribution Channel
  • 7.2.8. Mexico Deferiprone Market
    • 7.2.8.1. Market Size and Forecast, By Form
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By Distribution Channel
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Form
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By Distribution Channel
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Deferiprone Market
    • 7.3.6.1. Market Size and Forecast, By Form
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By Distribution Channel
  • 7.3.7. Germany Deferiprone Market
    • 7.3.7.1. Market Size and Forecast, By Form
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By Distribution Channel
  • 7.3.8. Italy Deferiprone Market
    • 7.3.8.1. Market Size and Forecast, By Form
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3.9. Spain Deferiprone Market
    • 7.3.9.1. Market Size and Forecast, By Form
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By Distribution Channel
  • 7.3.10. UK Deferiprone Market
    • 7.3.10.1. Market Size and Forecast, By Form
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By Distribution Channel
  • 7.3.11. Rest of Europe Deferiprone Market
    • 7.3.11.1. Market Size and Forecast, By Form
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Form
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By Distribution Channel
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Deferiprone Market
    • 7.4.6.1. Market Size and Forecast, By Form
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By Distribution Channel
  • 7.4.7. Japan Deferiprone Market
    • 7.4.7.1. Market Size and Forecast, By Form
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By Distribution Channel
  • 7.4.8. India Deferiprone Market
    • 7.4.8.1. Market Size and Forecast, By Form
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By Distribution Channel
  • 7.4.9. South Korea Deferiprone Market
    • 7.4.9.1. Market Size and Forecast, By Form
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By Distribution Channel
  • 7.4.10. Australia Deferiprone Market
    • 7.4.10.1. Market Size and Forecast, By Form
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By Distribution Channel
  • 7.4.11. Rest of Asia-Pacific Deferiprone Market
    • 7.4.11.1. Market Size and Forecast, By Form
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Form
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By Distribution Channel
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Deferiprone Market
    • 7.5.6.1. Market Size and Forecast, By Form
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By Distribution Channel
  • 7.5.7. South Africa Deferiprone Market
    • 7.5.7.1. Market Size and Forecast, By Form
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By Distribution Channel
  • 7.5.8. Saudi Arabia Deferiprone Market
    • 7.5.8.1. Market Size and Forecast, By Form
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By Distribution Channel
  • 7.5.9. Rest of LAMEA Deferiprone Market
    • 7.5.9.1. Market Size and Forecast, By Form
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Apotex Inc
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Cipla Limited
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. VHB Life Sciences Limited
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Taro Pharmaceutical Industries Ltd.
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Sun Pharmaceutical Industries Ltd.
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Novartis International AG
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Chiesi Farmaceutici S.p.A
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Zydus Cadila
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Cipla Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Pfizer
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료